Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 5/20 | 0.58 |
| ▸ | HTR2C | P28335 | 2/20 | 0.58 |
| ▸ | HTR7 | P34969 | 2/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | HTR6 | P50406 | 1/20 | 0.49 |
| ▸ | RPS6KB1 | P23443 | 4/20 | 0.47 |
| ▸ | DHODH | Q02127 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | PDE2A | O00408 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31489727 | 0.91 | HTR2A (0.55) | HTR2AHTR2CHTR7CYP2D6HTR6 | |
| SCHEMBL3051979 | 0.91 | HTR2A (0.55) | HTR2AHTR2CHTR7CYP2D6HTR6 | |
| SCHEMBL30910924 | 0.90 | HTR2A (0.51) | HTR2AHTR2CHTR7CYP2D6HTR6 | |
| SCHEMBL26326631 | 0.90 | DHODH (0.54) | HTR2AHTR2CHTR7CYP2D6HTR6 | |
| SCHEMBL16861567 | 0.86 | HTR2A (0.51) | HTR2AHTR2CHTR7CYP2D6HTR6 | |
| SCHEMBL16861667 | 0.86 | HTR2A (0.51) | HTR2AHTR2CHTR7CYP2D6HTR6 | |
| SCHEMBL15994961 | 0.86 | HTR2A (0.51) | HTR2AHTR2CHTR7CYP2D6HTR6 | |
| SCHEMBL3303526 | 0.86 | HTR2A (0.51) | HTR2AHTR2CHTR7CYP2D6HTR6 | |
| SCHEMBL21911551 | 0.85 | HTR2A (0.50) | HTR2AHTR2CHTR7CYP2D6HTR6 | |
| SCHEMBL3394400 | 0.83 | HTR2A (0.64) | HTR2AHTR2CHTR7CYP2D6HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109810572-A | Inorganic nano material prints ink and its preparation method and application | 深圳TCL工业研究院有限公司 | 2019-05-28 | — | — | CN | claimed |
| WO-2025072395-A1 | TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-04-03 | — | — | WO | disclosed |
| US-11866430-B2 | Naphthyridinone compounds useful as T cell activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-01-09 | — | — | US | disclosed |
| CN-112585139-B | Naphthyridinone compounds as T cell activators | 百时美施贵宝公司 | 2023-12-01 | — | — | CN | disclosed |
| EP-3814347-B1 | NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-05-03 | — | — | EP | disclosed |
| US-20210277004-A1 | NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2021-09-09 | — | — | US | disclosed |
| EP-3814347-A1 | NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | Bristol-Myers Squibb Company (US) | 2021-05-05 | — | — | EP | disclosed |
| CN-109810568-A | Inorganic nano material prints ink and its preparation method and application | TCL集团股份有限公司 | 2019-05-28 | — | — | CN | disclosed |
| CN-109810572-A | Inorganic nano material prints ink and its preparation method and application | 深圳TCL工业研究院有限公司 | 2019-05-28 | — | — | CN | disclosed |
| CN-109810567-A | Inorganic nano material prints ink and its preparation method and application | TCL集团股份有限公司 | 2019-05-28 | — | — | CN | disclosed |
| WO-1997040044-A1 | HETEROCYCLIC COMPOUNDS | ELI LILLY AND COMPANY (US) | 1997-10-30 | — | — | WO | disclosed |
| EP-0131302-B1 | IMIDAZOLIUM SALTS, INTERMEDIATES THERETO AND THEIR USE | SCHERING AKTIENGESELLSCHAFT (DE) | 1992-01-29 | — | — | EP | disclosed |
| US-4689341-A | Antiarrhythmic imidazoles | SCHERING A.G. (DE) | 1987-08-25 | — | — | US | disclosed |
| US-4613609-A | Antiarrhythmic imidazoliums | SCHERING A. G. (DE) | 1986-09-23 | — | — | US | disclosed |
| US-4581370-A | Antiarrhythmic imidazoliums | SCHERING A.G. (DE) | 1986-04-08 | — | — | US | disclosed |
| EP-0131302-A2 | Imidazolium salts, intermediates thereto and their use | SCHERING AKTIENGESELLSCHAFT (DE) | 1985-01-16 | — | — | EP | disclosed |
| US-4395410-A | Quaternary ammonium antiarrhythmic drugs | ELI LILLY AND COMPANY (US) | 1983-07-26 | — | — | US | disclosed |
| EP-0002604-B1 | QUATERNARY AMMONIUM SALTS, AND THEIR FORMULATIONS AND PREPARATION | ELI LILLY AND COMPANY (US) | 1983-05-04 | — | — | EP | disclosed |
| US-4289787-A | PROLONG ACTION POTENTIAL OF CARDIAC TISSUE | ELI LILLY AND COMPANY (US) | 1981-09-15 | — | — | US | disclosed |
| EP-0002604-A1 | Quaternary ammonium salts, and their formulations and preparation | ELI LILLY AND COMPANY (US) | 1979-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11866430-B2 | Naphthyridinone compounds useful as T cell activators | DGKZ, DGKA, DGKG | HTR2A 4792/4885HTR2C 4771/4885HTR7 4449/4885 |
| US-20210277004-A1 | NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | DGKZ, DGKA, DGKG | HTR2A 4792/4885HTR2C 4771/4885HTR7 4449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.